{"id":"W2907212631","doi":"10.1016/j.cllc.2018.12.022","title":"Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol","year":2019,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Janssen Pharmaceuticals; Merck Sharp and Dohme; Genentech; Takeda Pharmaceutical Company; AbbVie; Celgene; Medtronic; Novartis; Sanofi; Merck; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Roche; Astellas Pharma US; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Medicine; Afatinib; Pembrolizumab; Squamous-cell carcinoma of the lung; Lung; Lung cancer; Oncology; Internal medicine; Basal cell; Cancer; Immunotherapy; Gefitinib; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004672471,0.00229453,0.002431393,0.0004943247,0.001511955,0.001914578,0.002816395,0.003484042,0.04262384],"category_scores_gemma":[0.003534583,0.0009189108,0.002331501,0.0007962476,0.0007747155,0.00160547,0.0009399358,0.004024324,0.01196304],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002653104,"about_ca_system_score_gemma":0.008218849,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00264134,"about_ca_topic_score_gemma":0.008573716,"domain_scores_codex":[0.9982803,0.0009130011,0.0001531468,0.0002061898,0.0001668708,0.0002805447],"domain_scores_gemma":[0.9984999,0.000217477,0.0003077972,0.0001573084,0.0002748073,0.0005427359],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.7466157,0.01210634,0.003449177,0.01255948,0.001593656,0.0004325711,0.0002826146,0.001653635,0.006747227,0.00327554,0.131797,0.07948706],"study_design_scores_gemma":[0.8440114,0.03099377,0.006183038,0.001747137,0.000885314,0.0002841931,0.0001055236,0.001028397,0.00128577,0.001832099,0.1115718,0.00007164163],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.04549194,0.006185442,0.004034211,0.004297364,0.00129365,0.8467755,0.05107305,0.0004991181,0.04034974],"genre_scores_gemma":[0.07141628,0.004240654,0.006814867,0.006450983,0.0005492402,0.8736197,0.02073225,0.00009213262,0.0160839],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.04262384,"threshold_uncertainty_score":0.142591,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01969337257832399,"score_gpt":0.3966256232321059,"score_spread":0.3769322506537819,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}